Zymeworks recently reported Phase 1 data for its folate receptor alpha-targeting ADC ZW191, showing meaningful anti-tumor activity and a manageable safety profile in platinum-resistant ovarian and ...
Source LinkZymeworks recently reported Phase 1 data for its folate receptor alpha-targeting ADC ZW191, showing meaningful anti-tumor activity and a manageable safety profile in platinum-resistant ovarian and ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.